

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

**VOLUNTARY ANNOUNCEMENT
IN RELATION TO
THE 2026 H SHARE REPURCHASE PLAN**

This announcement is made on a voluntary basis by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”, together with its subsidiaries, collectively the “**Group**”).

Based on confidence in the Group's development prospects and in recognition of its intrinsic value, pursuant to the general mandate (the “**H Share Repurchase Mandate**”) to repurchase H shares of the Company (the “**H Shares**”) granted to the board of directors of the Company (the “**Board**”) by the shareholders of the Company at the annual general meeting, the class meeting of H shareholders, and the class meeting of A shareholders of the Company held on 16 June 2026, and upon the approvals of the Board, the Company has proposed to repurchase H Shares during the 12 months commencing from 27 August 2026, with the proposed total amount of funds for repurchasing H Shares of up to HK\$1 billion (the “**2026 H Share Repurchase Plan**”). The use of such H Shares so repurchased will be decided by the Company in accordance with the H Share Repurchase Mandate and factors such as market conditions, including but not limited to cancellation of the H Shares so repurchased, or holding the same as treasury shares.

The Board is highly confident in the Group's business development and outlook, and considers that the current price of the H Share is below its actual value. Therefore, the Board believes that it is in the best interests of the Company and its shareholders as a whole to implement the share repurchase plan.

Shareholders and potential investors should note that, in the event that the implementation of the 2026 H Share Repurchase Plan has not been completed by the conclusion of the next annual general meeting of the Company, the continuation of the relevant repurchases under such plan shall be subject to the approval(s) of general mandate to repurchase the relevant H Shares by the general meeting as well as relevant class meetings of H shareholders and A shareholders (if applicable). Any repurchase will be subject to market conditions and shall comply with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the Codes on Takeovers and Mergers and Share Buy-backs and other applicable laws and regulations, any

regulatory requirements of the venue at which the Company's shares are listed as well as the rules of the articles of association of the Company. The Company makes no assurance as to the timing, quantity or price of any repurchases. Accordingly, shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company.

By Order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Yuqing
Chairman

Shanghai, the PRC
6 September 2026

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* For identification purposes only